| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803049901028 | 304990102 | VIZARSIN F.C.TAB 25MG/TAB BTx4x1 δισκίο σε BLISTER (PVC/alu) σε BLISTER (PVC/alu) | 10.67 | 11.25 | 16.09 |
| 05/2018 | 2803049902025 | 304990202 | VIZARSIN F.C.TAB 50MG/TAB BTx4x1 δισκίο σε BLISTER (PVC/alu) σε BLISTER (PVC/alu) | 13.07 | 13.78 | 19.72 |
| 05/2018 | 2803049903022 | 304990302 | VIZARSIN F.C.TAB 100MG/TAB BTx4x1 δισκίο σε BLISTER (PVC/alu) σε BLISTER (PVC/alu) | 15.68 | 16.53 | 23.66 |
| 05/2018 | 2803049905033 | 304990503 | VIZARSIN OR.DISP.TA 50MG/TAB BTx4x1 δισκίο σε BLISTER (OPA/AL/PVC/PET/AL) σε BLISTER (OPA/AL/PVC/PET/AL) | 12.42 | 13.09 | 18.73 |
| 05/2018 | 2803049906030 | 304990603 | VIZARSIN OR.DISP.TA 100MG/TAB BTx4x1 δισκίο σε BLISTER (OPA/AL/PVC/PET/AL) σε BLISTER (OPA/AL/PVC/PET/AL) | 14.90 | 15.70 | 22.46 |
For the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).
Sildenafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by sildenafil enhances erectile function by increasing the amount of cGMP.
>90% absorbed with ~40% reaching systemic circulation unchanged following first-pass metabolism
4 hours
Sildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).
* 105 L